

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Midcap Funding III, LLC		02/08/2013	LIMITED LIABILITY COMPANY: DELAWARE
RECEIVING PARTY DATA			
Name:	CeNeRx BioPharma, Inc.		
Street Address:	270 Cornerstone Drive Suite 103		
City:	Cary		
State/Country:	NORTH CAROLINA		
Postal Code:	27519		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	3662094	CENERX	
Registration Number:	3687175	TRIRIMA	
Serial Number:	77807249	AYRENE	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	919-781-4000		
Email:	lblackwell@wyrick.com		
Correspondent Name:	Linda Blackwell		
Address Line 1:	4101 Lake Boone Trail Suite 300		
Address Line 2:	Wyrick Robbins Yates & Ponton LLP		
Address Line 4:	Raleigh, NORTH CAROLINA 27607		
ATTORNEY DOCKET NUMBER:	20515.1 LFB (765047)		

OP \$90.00 3662094

NAME OF SUBMITTER:	Robert Goodridge, General Counsel
Signature:	/Robert Goodridge/
Date:	03/19/2013
Total Attachments: 6 source=Midcap Funding III LLC Release#page1.tif source=Midcap Funding III LLC Release#page2.tif source=Midcap Funding III LLC Release#page3.tif source=Midcap Funding III LLC Release#page4.tif source=Midcap Funding III LLC Release#page5.tif source=Midcap Funding III LLC Release#page6.tif	

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

THIS RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST made and entered effective as of February 8, 2013, by the below signatory hereto (the "Lender"), in favor of CeNeRx BioPharma, Inc., a Delaware corporation, (the "Borrower").

WHEREAS, Lender and Borrower were parties to a certain Intellectual Property Security Agreement dated as of February 19, 2010 (the "Security Agreement") and recorded in the United States Patent and Trademark Office on February 23, 2010 at Reel 4154/ Frame 0337, and at Reel 023973/Frame 0396, under which Borrower granted Lender a security interest in Borrower's trademarks and patents, including but not limited to the trademarks and patents listed on Schedule A hereto; and

WHEREAS, Lender now desires to release and terminate any security interest it may have as to the trademarks and patents listed on Schedule A (the "Security Interest").

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Lender hereby terminates the Security Interest and releases to Borrower all interest which Lenders possess or are otherwise entitled to in the patents and trademarks listed on Schedule A hereto by virtue of such Security Agreement.

[Signature page follows.]

IN WITNESS WHEREOF, the undersigned have executed this Release of Intellectual Property Security Interest as of the date first above written.

LENDER:

MIDCAP FUNDING III, LLC

By: 

Name: Robert Goodridge

Title: General Counsel

SCHEDULE A

Copyrights

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
NONE	N/A	N/A

PATENTS

<u>Title</u>	<u>Patent/Patent Application Number (Publication Number)</u>	<u>Issue/Filing Date</u>
Methods of treating Rett Syndrome	12/117,586 20080280983	05/08/2008
Dialkylamino Alkyl Esters of Pivagabine as Medicaments for the Treatment of Central Nervous System Disorders	US 7,632,836 20090111813	12/15/2009
Polymorphic Form Of Fluoro-7-(2,2,2-Trifluoroethoxy) Phenoxathiin-10,10-Dioxide	US 7,812,050 11/773,892 20080009542	10/12/2010 07/05/2007 01/10/2008
Oral Enteric Antidepressant Formulation	13/143,408 20120003303	01/08/2010 01/05/2012
Oral Sustained Release Antidepressant Formulation	13/143,403 20120003274	01/08/2010 01/05/2012
Pharmaceutical Compounds ✓	12/330,434 20090081123	12/08/2008
Methods of treating Rett Syndrome	PCT/US2008/063129	11/20/2008
Dialkylamino Alkyl Esters of Pivagabine as Medicaments for the Treatment of Central Nervous System Disorders	PCT/US2007/024547	06/05/2008
Polymorphic Form Of Fluoro-7-(2,2,2-Trifluoroethoxy) Phenoxathiin-10,10-Dioxide	PCT/US2007/015533	01/17/2008
Oral Antidepressant Formulation with Reduced Excipient Load	US 8,313,766 12/860,358 20110206769	11/20/2012 08/20/2010 08/25/2011

TRADEMARKS

<u>Description</u>	<u>Registration/Application Number</u>	<u>Registration/Application Date</u>
CENERX	3,662,094	07/28/2009
CENERX (Canada)	1,333,088	01/29/2007
MERIMA	77/467,853	05/07/2008
MYRIMA	77/467,852	05/07/2008
ATYRIMA	77/467,850	05/07/2008
TRIRIMA	3,687,175	09/22/2009
ATYREMA	77/478,437	05/19/2008
TYRIMA	77/094,042	01/29/2007
AYRENE	77/807,249	08/18/2009

SCHEDULE D

Mask Works

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
NONE	N/A	N/A